Mitochondrial remodeling and ischemic protection by G protein-coupled receptor 35 agonists

被引:65
|
作者
Wyant, Gregory A. [1 ,2 ]
Yu, Wenyu [1 ]
Doulamis, IIias P. [3 ]
Nomoto, Rio S. [3 ]
Saeed, Mossab Y. [3 ]
Duignan, Thomas [3 ]
McCully, James D. [3 ]
Kaelin Jr, William G. [1 ,2 ,4 ]
机构
[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA
[2] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA
[3] Harvard Med Sch, Boston Childrens Hosp, Dept Cardiac Surg, Dept Surg, Boston, MA 02215 USA
[4] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Boston, MA 02215 USA
基金
美国国家卫生研究院;
关键词
ATPASE INHIBITORY FACTOR-1; KYNURENIC ACID; RESPIRATORY PARAMETERS; MYOCARDIAL-INFARCTION; LIGAND; GPR35; EXPRESSION; BRAIN; IF1; METABOLITES;
D O I
10.1126/science.abm1638
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Kynurenic acid (KynA) is tissue protective in cardiac, cerebral, renal, and retinal ischemia models, but the mechanism is unknown. KynA can bind to multiple receptors, including the aryl hydrocarbon receptor, the a7 nicotinic acetylcholine receptor (a7nAChR), multiple ionotropic glutamate receptors, and the orphan G protein-coupled receptor GPR35. Here, we show that GPR35 activation was necessary and sufficient for ischemic protection by KynA. When bound by KynA, GPR35 activated G(i)- and G(12/13)-coupled signaling and trafficked to the outer mitochondria membrane, where it bound, apparantly indirectly, to ATP synthase inhibitory factor subunit 1 (ATPIF1). Activated GPR35, in an ATPIF1-dependent and pertussis toxin-sensitive manner, induced ATP synthase dimerization, which prevented ATP loss upon ischemia. These findings provide a rationale for the development of specific GPR35 agonists for the treatment of ischemic diseases.
引用
收藏
页码:621 / 629
页数:9
相关论文
共 50 条
  • [1] Discovery of Natural Phenols as G Protein-Coupled Receptor-35 (GPR35) Agonists
    Deng, Huayun
    Hu, Haibei
    Ling, Shizhang
    Ferrie, Ann M.
    Fang, Ye
    ACS MEDICINAL CHEMISTRY LETTERS, 2012, 3 (02): : 165 - 169
  • [2] Partial agonists and G protein-coupled receptor desensitization
    Clark, RB
    Knoll, BJ
    Barber, R
    TRENDS IN PHARMACOLOGICAL SCIENCES, 1999, 20 (07) : 279 - 286
  • [3] Covalent agonists for studying G protein-coupled receptor activation
    Weichert, Dietmar
    Kruse, Andrew C.
    Manglik, Aashish
    Hiller, Christine
    Zhang, Cheng
    Huebner, Harald
    Kobilka, Brian K.
    Gmeiner, Peter
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2014, 111 (29) : 10744 - 10748
  • [4] Anti-Inflammatory Gallic Acid and Wedelolactone Are G Protein-Coupled Receptor-35 Agonists
    Deng, Huayun
    Fang, Ye
    PHARMACOLOGY, 2012, 89 (3-4) : 211 - 219
  • [5] Novel inverse agonists for the orphan G protein-coupled receptor 6
    Laun, Alyssa S.
    Shrader, Sarah H.
    Song, Zhao-Hui
    HELIYON, 2018, 4 (11):
  • [6] The physiological response to cardiovascular 'orphan' G protein-coupled receptor agonists
    Joshua M. Hare
    David A. Kass
    Jonathan S. Stamler
    Nature Medicine, 1999, 5 : 1241 - 1242
  • [7] The physiological response to cardiovascular 'orphan' G protein-coupled receptor agonists
    Hare, JM
    Kass, DA
    Stamler, JS
    NATURE MEDICINE, 1999, 5 (11) : 1241 - 1242
  • [8] Discovery of endogenous inverse agonists for G protein-coupled receptor 6
    Shrader, Sarah H.
    Song, Zhao-Hui
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2020, 522 (04) : 1041 - 1045
  • [9] G Protein-coupled Receptor Kinase 5 in Fibrotic Tissue Remodeling
    Cuong Tran-Manh
    Thuong Trinh-Minh
    Liebel, Christoph
    Chen, Chih-Wei
    Distler, Joerg
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 1858 - 1859
  • [10] Development and Characterization of Fluorescent Probes for the G Protein-Coupled Receptor 35
    Wei, Lai
    Xiang, Kaijing
    Kang, Hongjian
    Yu, Yancheng
    Fan, Hongjie
    Zhou, Han
    Hou, Tao
    Ge, Yonglin
    Wang, Jixia
    Guo, Zhimou
    Chen, Yang
    Zhao, Yaopeng
    Liang, Xinmiao
    ACS MEDICINAL CHEMISTRY LETTERS, 2023, 14 (04): : 411 - 416